drugset / Trial / NCT02963077
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of A4250 after single or multiple oral doses in healthy subjects. In addition, will evaluate A4250 in combination with cholestyramine.
Timeline
- Start
- 2013-07
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cholestyramine | Other / unclassified | 1 mg | — |
| Subject | Cholestyramine | Other / unclassified | 1 g | — |
| Subject | Odevixibat | Small molecule | 0.1 mg | Oral |
| Subject | Odevixibat | Small molecule | 0.3 mg | Oral |
| Subject | Odevixibat | Small molecule | 1 mg | Oral |
| Subject | Odevixibat | Small molecule | 1.5 mg | Oral |
| Subject | Odevixibat | Small molecule | 3 mg | Oral |
| Subject | Odevixibat | Small molecule | 10 mg | Oral |